News for Verastem, Inc. (VSTM)

Verastem Oncology's VS-7375 earns FDA fast track for KRAS G12D-mutated pancreatic cancer. Read more here.

PR NewswireVANCOUVER, BC, July 23, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, July 23, 2025 /PRNewswire/

Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 ’25 revenue anticipated to be $20.4 million and Company reiterates previously announced Q2 ‘25 gross margin guidance

Verastem's FDA approval for KRAS-mutant LGSOC, strong pipeline, and catalysts signal growth potential. Click here to read an analysis of VSTM stock now.

Verastem (VSTM) has disclosed findings from its Phase 2 RAMP 201 clinical trial, which is now available online in the Journal of Clinical Oncology. The study re

Verastem shows strong late-stage pipeline progress, financial discipline, and a diverse portfolio that support long-term growth. Learn why VSTM stock is a buy.

FibroGen (FGEN) has appointed Dr. Michael Kauffman to its Board of Directors, effective June 4, 2025. Dr. Kauffman brings 30 years of life sciences industry

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 0.2% on Monday. The Dow traded down 0.49% to 42,064.07 while the NASD...

Verastem (VSTM) Oncology has shared encouraging results from the Phase 1/2 trial of GFH375, focusing on dose escalation for treating pancreatic ductal adenocarc

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today ann

In the opening quarter of 2025, Verastem (VSTM) Oncology has achieved significant milestones in its pipeline initiatives. The company has exercised an early opt

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today ann

Verastem Oncology (VSTM) reports Q1 2025 results with a slight EPS miss.

Learn about Verastem's (VSTM) recent filing to sell 3.43M shares of common stock.

B. Riley has elevated its price target for Verastem (VSTM) from $12 to $13, maintaining a Buy rating on the stock. The upward revision comes as Verastem announc

On May 9, 2025, HC Wainwright & Co. analyst Sean Lee maintained a "Buy" rating on Verastem (VSTM). The financial services firm raised its price target for VSTM

RBC Capital's analyst has elevated Verastem's (VSTM) price target from $14 to $16 while maintaining an Outperform rating on its stock. This upgrade reflects Ver

Jefferies analyst Kelly Shi has boosted the price target for Verastem (VSTM) to $19 from the previous $15 while maintaining a Buy rating on the company's stock.

Verastem (VSTM) has announced a conference call slated for May 1 at 11 a.m., featuring its President & CEO, Paterson, along with Chief Scientific Officer, Pacht